Clara E Gavira-O'Neill1, Jie-Xian Dong1,2, James S Trimmer1. 1. Department of Physiology and Membrane Biology, University of California Davis School of Medicine, Davis, California. 2. Current address: Research Center for Innovative Anti-Cancer Drugs, Research Institute of Tsinghua University in Shenzhen, Shenzhen, China.
Abstract
Nanobodies (nAbs) are recombinant antigen-binding variable domain fragments obtained from heavy-chain-only immunoglobulins. Among mammals, these are unique to camelids (camels, llamas, alpacas, etc.). Nanobodies are of great use in biomedical research due to their efficient folding and stability under a variety of conditions, as well as their small size. The latter characteristic is particularly important for nAbs used as immunolabeling reagents, since this can improve penetration of cell and tissue samples compared to conventional antibodies, and also reduce the gap distance between signal and target, thereby improving imaging resolution. In addition, their recombinant nature allows for unambiguous definition and permanent archiving in the form of DNA sequence, enhanced distribution in the form of sequences or plasmids, and easy and inexpensive production using well-established bacterial expression systems, such as the IPTG induction method described here. This article will review the basic workflow and process for developing, screening, and validating novel nAbs against neuronal target proteins. The protocols described make use of the most common nAb development method, wherein an immune repertoire from an immunized llama is screened via phage display technology. Selected nAbs can then be taken through validation assays for use as immunolabels or as intrabodies in neurons.
Nanobodies (nAbs) are recombinant antigen-binding variable domain fragments obtained from heavy-chain-only immunoglobulins. Among mammals, these are unique to camelids (camels, llamas, alpacas, etc.). Nanobodies are of great use in biomedical research due to their efficient folding and stability under a variety of conditions, as well as their small size. The latter characteristic is particularly important for nAbs used as immunolabeling reagents, since this can improve penetration of cell and tissue samples compared to conventional antibodies, and also reduce the gap distance between signal and target, thereby improving imaging resolution. In addition, their recombinant nature allows for unambiguous definition and permanent archiving in the form of DNA sequence, enhanced distribution in the form of sequences or plasmids, and easy and inexpensive production using well-established bacterial expression systems, such as the IPTG induction method described here. This article will review the basic workflow and process for developing, screening, and validating novel nAbs against neuronal target proteins. The protocols described make use of the most common nAb development method, wherein an immune repertoire from an immunized llama is screened via phage display technology. Selected nAbs can then be taken through validation assays for use as immunolabels or as intrabodies in neurons.
Authors: K Martin Chow; Sidney W Whiteheart; Jeffrey R Smiley; Savita Sharma; Kathy Boaz; Meggie J Coleman; Alvina Maynard; Louis B Hersh; Craig W Vander Kooi Journal: J Vis Exp Date: 2019-01-26 Impact factor: 1.355
Authors: Mathias Uhlen; Anita Bandrowski; Steven Carr; Aled Edwards; Jan Ellenberg; Emma Lundberg; David L Rimm; Henry Rodriguez; Tara Hiltke; Michael Snyder; Tadashi Yamamoto Journal: Nat Methods Date: 2016-09-05 Impact factor: 28.547
Authors: Els Pardon; Toon Laeremans; Sarah Triest; Søren G F Rasmussen; Alexandre Wohlkönig; Armin Ruf; Serge Muyldermans; Wim G J Hol; Brian K Kobilka; Jan Steyaert Journal: Nat Protoc Date: 2014-02-27 Impact factor: 13.491